155 related articles for article (PubMed ID: 23559890)
1. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.
Tam VC; Ko YJ; Mittmann N; Cheung MC; Kumar K; Hassan S; Chan KK
Curr Oncol; 2013 Apr; 20(2):e90-e106. PubMed ID: 23559890
[TBL] [Abstract][Full Text] [Related]
2. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
[TBL] [Abstract][Full Text] [Related]
4. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System.
Coyle D; Ko YJ; Coyle K; Saluja R; Shah K; Lien K; Lam H; Chan KK
Value Health; 2017 Apr; 20(4):586-592. PubMed ID: 28408000
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.
Attard CL; Brown S; Alloul K; Moore MJ
Curr Oncol; 2014 Feb; 21(1):e41-51. PubMed ID: 24523620
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
[TBL] [Abstract][Full Text] [Related]
10. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.
Lien K; Tam VC; Ko YJ; Mittmann N; Cheung MC; Chan KK
Curr Oncol; 2015 Dec; 22(6):e443-52. PubMed ID: 26715881
[TBL] [Abstract][Full Text] [Related]
11. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer.
Bao K; Li X; He X; Jian L
Clin Ther; 2021 Jun; 43(6):1107-1115. PubMed ID: 34059328
[TBL] [Abstract][Full Text] [Related]
14. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
Leung HW; Chan AL; Muo CH
Clin Ther; 2016 May; 38(5):1174-83. PubMed ID: 27033672
[TBL] [Abstract][Full Text] [Related]
17. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
